Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2010 (2010), Article ID 167045, 10 pages
Research Article

Identification of a New Peptide for Fibrosarcoma Tumor Targeting and Imaging In Vivo

1Graduate Institute of Clinical Medicine, Taipei Medical University, Taipei 11031, Taiwan
2Department of Otolaryngology, Wan-Fang Hospital, Taipei Medical University, Taipei 116, Taiwan
3Institute of Biomedical Materials and Engineering, Taipei Medical University, 250 Wu-Hsing Street, Taipei 110, Taiwan
4Institute of Biochemistry and Molecular Biology, National Yang-Ming University, Taipei 112, Taiwan
5Genomics research Center, Academia Sinica, Taipei 115, Taiwan
6Section of Hematology-Oncology, Department of Medicine, Taipei Medical University, Taipei 11217, Taiwan
7Graduate Institute of Life Sciences, National Defense Medical Center, Taipei 114, Taiwan
8Institute of Radiological Science, National Yang-Ming University, Taipei 112, Taiwan
9Institute of Nuclear Energy Research, Taoyuan 32546, Taiwan
10Department of Surgery, School of Medicine, Taipei Medical University-Shuang Ho Hospital, Taipei 110, Taiwan
11Department of Microbiology and Immunology, School of Medicine, Taipei Medical University, 250 Wu-Hsing Street, Taipei 110, Taiwan

Received 14 April 2010; Revised 9 August 2010; Accepted 2 October 2010

Academic Editor: Elvira Gonzalez De Mejia

Copyright © 2010 Chia-Che Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


A 12-mer amino acid peptide SATTHYRLQAAN, denominated TK4, was isolated from a phage-display library with fibrosarcoma tumor-binding activity. In vivo biodistribution analysis of TK4-displaying phage showed a significant increased phage titer in implanted tumor up to 10-fold in comparison with normal tissues after systemic administration in mouse. Competition assay confirmed that the binding of TK4-phage to tumor cells depends on the TK4 peptide. Intravenous injection of 131I-labeled synthetic TK4 peptide in mice showed a tumor retention of 3.3% and 2.7% ID/g at 1- and 4-hour postinjection, respectively. Tumor-to-muscle ratio was 1.1, 5.7, and 3.2 at 1-, 4-, and 24-hour, respectively, and tumors were imaged on a digital γ-camera at 4-hour postinjection. The present data suggest that TK4 holds promise as a lead structure for tumor targeting, and it could be further applied in the development of diagnostic or therapeutic agent.